When markets fall, a takeover target’s one-year share price high is a stubborn benchmark for pricing a deal 🔒
The biotech sector is more than 40% down from its high in February 2021, while the major pharmaceutical firms are flush with cash. That sounds like the ideal condition for deal-making. But what if biotech boards and shareholders want takeover bids at yesterday’s sky-high prices?
It was found in a 2020 study by JPMorgan Chase & Co analysts that when markets fall, a takeover target’s one-year share price high is a stubborn benchmark for pricing a deal. So it can take more than a year from a market correction until buyers and sellers align. Those dynamics may now be at work...
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US biotech tycoon opens Africa's first end-to-end COVID-19 jab plantUS biotech billionaire Patrick Soon-Shiong opened a plant in Cape Town that will be the first in Africa to produce COVID-19 vaccines from start to finish.
Read more »
Richemont records over 30% sales growth in three months to DecemberJSE-listed Richemont reported that it has exceeded pre-pandemic sales levels across all its operating regions after posting a 32% jump in sales – at constant exchange rates – for the three months ended 31 December 2021 Moneyweb CompanyNews Matshoba_A
Read more »
Microsoft to buy Call of Duty maker Activision Blizzard for $69bnThe deal is the biggest cash takeover of the pandemic
Read more »
Gold prices fall as US yields firmInvestors await cues from US Federal Reserve on timeline for rate hikes
Read more »
Bitcoin’s dominance declines as altcoins take over[SPONSORED] Bitcoin’s dominance of the crypto space has declined from 100% a decade ago to around 42% today. OVEXIO Moneyweb altcoins
Read more »